Special Issue "Blood–Brain Barrier Drug Targeting: The Future of Brain Drug Development"
Deadline for manuscript submissions: closed (10 March 2022) | Viewed by 29404
Interests: blood–brain barrier; pain therapeutics; drug delivery; drug development; CNS targeting
Special Issues, Collections and Topics in MDPI journals
Neurological disorders have been a challenge to target therapeutically given the presence of the blood–brain barrier (BBB). Blood–brain barrier (BBB)/Neurovascular unit (NVU) integrity is vital to the health of the central nervous system (CNS) and serves as the gateway for CNS drug delivery. However, the influence of pathological changes on BBB dynamics and ultimately on brain drug development is oft overlooked. Thus, it is important to the clinical success of new CNS-targeting agents to account for pathological changes, as well as those resulting from aging and sex differences, to fully understand BBB integrity, its impact on drug delivery, and how these issues will be addressed in the future.
The aim of this Special Issue of Pharmaceutics is to collect research and review papers on targeting the CNS during disease by understanding the role of the BBB in drug discovery and development. We welcome articles dealing with any aspect of BBB dynamics during physiological and pathophysiological states on CNS drug delivery and invite researchers and drug developers to publish their original research or review articles with expert opinions and perspectives in the area of therapeutics.
Dr. Tally M. Largent-Milnes
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- blood–brain barrier
- drug delivery
- CNS targeting
- drug development
- pathologic influence on the neurovascular unit